Development of biodegradable nanoparticles for liver-specific ribavirin delivery

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 4005-4011

  Ishihara, Tsutomu ^a   Kaneko, Kohei ^a   Ishihara, Tomoaki ^b   Mizushima, Tohru ^b  

^a NIHON UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Controlled release; Encapsulation; Hepatocytes; Nanoparticles; Polymer biodegradation; Polymeric drug carrier; Site specific delivery

Indexed keywords

ARABINOGALACTAN; DRUG CARRIER; FERRIC ION; GALAPTIN; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLYLACTIC ACID; RIBAVIRIN; ANTIVIRUS AGENT; BIOMATERIAL; DELAYED RELEASE FORMULATION; EXCIPIENT; GALACTAN; LACTIC ACID; POLYLYSINE; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; DIFFUSION; DRUG DELIVERY SYSTEM; ENCAPSULATION; FEMALE; HEPG2 CELL LINE; INTERNALIZATION; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; HEPATITIS C, CHRONIC; HUMAN; LIVER; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; GALACTANS; HEP G2 CELLS; HEPATITIS C, CHRONIC; HUMANS; LACTIC ACID; LIVER; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYLYSINE; POLYMERS; RIBAVIRIN;

EID: 84914814648     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24219     Document Type: Article

References (38)

1. Pawlotsky JM. 2013. Hepatitis C virus: Standard-of-care treatment. Adv Pharmacol 67:169-215.
2. Thitinan S, McConville JT. 2009. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 369(1-2):121-135.
3. Virovic L, Wu CH, Konishi M, Wu GY. 2005. Novel delivery methods for treatment of viral hepatitis: An update. Expert Opin Drug Deliv 2(4):707-717.
4. Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Franc¸ois C. 2010. Ribavirin monitoring in chronic hepatitis C therapy: Anaemia versus efficacy. Antivir Ther 15(5):687-695.
5. Matthews SJ, Lancaster JW. 2012. Telaprevir: A hepatitis C NS3/4A protease inhibitor. Clin Ther 34(9):1857-1882.
6. Fiume L, Mattioli A, Busi C, Balboni PG, Barbanti-Brodano G, De Vries J, Altmann R, Wieland T. 1980. Selective inhibition of Ectromelia virus DNA synthesis in hepatocytes by adenine-9-beta- D-arabinofuranoside (ara-A) and adenine-9-beta-D-arabinofuranoside 5′-monophosphate (ara-AMP) conjugated to asialofetuin. FEBS Lett 116(2):185-188.
7. Torrani Cerenzia M, Fiume L, De Bernardi Venon W, Lavezzo B, Brunetto MR, Ponzetto A, Di Stefano G, Busi C, Mattioli A, Gervasi GB, Bonino F, Verme G. 1996. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 23(4):657-661.
8. Di Stefano G, Colonna FP, Bongini A, Busi C, Mattioli A, Fiume L. 1997. Ribavirin conjugated with lactosaminated poly-L-lysine: Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem Pharmacol 54(3):357-363.
9. Bijsterbosch MK, Ying C, de Vrueh RL, de Clercq E, Biessen EA, Neyts J, van Berkel TJ. 2001. Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol Pharmacol 60(3):521-527.
10. Levy GA, Adamson G, Phillips MJ, Scrocchi LA, Fung L, Biessels P, Ng NF, Ghanekar A, Rowe A, Ma MX, Levy A, Koscik C, He W, Gorczynski R, Brookes S, Woods C, McGilvray ID, Bell D. 2006. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology 43(3):581-591.
11. Chimalakonda KC, Agarwal HK, Kumar A, Parang K, Mehvar R. 2007. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconj Chem 18(6):2097-2108.
12. Fiume L, Di Stefano G, Busi C, Mattioli A, Bonino F, Torrani-Cerenzia M, Verme G, Rapicetta M, Bertini M, Gervasi GB. 1997. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J Viral Hepat 4(6):363-370.
13. Ishihara T, Mizushima T. 2010. Techniques for efficient entrapment of pharmaceuticals in biodegradable solid micro/nanoparticles. Expert Opin Drug Deliv 7(5):565-575.
14. Ishihara T, Takahashi M, Higaki M, Mizushima Y. 2009. Efficient encapsulation of a water-soluble corticosteroid in biodegradable nanoparticles. Int J Pharm 365(1-2):200-205.
15. Ishihara T, Takahashi M, Higaki M, Takenaga M, Mizushima T, Mizushima Y. 2008. Prolonging the in vivo residence time of prostaglandin E1 with biodegradable nanoparticles. Pharm Res 25(7):1686-1695.
16. Ishihara T, Takahashi M, Higaki M, Mizushima Y, Mizushima T. 2010. Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int J Pharm 385(1-2):170-175.
17. Ishihara T, Kubota T, Choi T, Higaki M. 2009. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther 329(2):412-417.
18. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. 2009. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 260(1):33-38.
19. Sakai T, Ishihara T, Higaki M, Akiyama G, Tsuneoka H. 2011. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 52(3):1516-1521.
20. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. 2006. Ribavirin-induced anemia: Mechanisms, risk factors and related targets for future research. Curr Med Chem 13(27):3351-3357.
21. Ashwell G, Harford J. 1982. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531-554.
22. Poelstra K, Prakash J, Beljaars L. 2012. Drug targeting to the diseased liver. J Control Release 161(2):188-197.
23. Pathak A, Vyas SP, Gupta KC. 2008. Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine 3(1):31-49.
24. Ishihara T, Kano A, Obara K, Saito M, Chen X, Park TG, Akaike T, Maruyama A. 2011. Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates. J Control Release 155(1):34-39.
25. Kaneo Y, Ueno T, Tanaka T, Iwase H, Yamaguchi Y, Uemura T. 2000. Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. Int J Pharm 201(1):59-69.
26. Shah SM, Pathak PO, Jain AS, Barhate CR, Nagarsenker MS. 2013. Synthesis, characterization, and in vitro evaluation of palmitoylated arabinogalactan with potential for liver targeting. Carbohydr Res 367:41-47.
27. Elgart A, Farber S, Domb AJ, Polacheck I, Hoffman A. 2010. Polysaccharide pharmacokinetics: Amphotericin B arabinogalactan conjugate - A drug delivery system or a new pharmaceutical entity? Biomacromolecules 11(8):1972-1977.
28. Park JU, Ishihara T, Kano A, Akaike T, Maruyama A. 1999. Preparation of dendritic graft copolymer consisting of poly-(L-lysine) and arabinogalactan as a hepatocyte specific DNA carrier. Prep Biochem Biotechnol 29(4):353-370.
29. Allen LB, Boswell KH, Khwaja TA, Meyer RB Jr, Sidwell RW, Witkowski JT, Christensen LF, Robins RK. 1978. Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin). J Med Chem 21(8):742-746.
30. Yasuno S, Murata T, Kokubo K, Yamaguchi T, Kamei M. 1997. Two-mode analysis by high-performance liquid chromatography of Daminobenzoic ethyl ester-derivatized monosaccharides. Biosci Biotechnol Biochem 61(11):1944-1946.
31. Loregian A, Scarpa MC, Pagni S, Parisi SG, Palù G. 2007. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 856(1-2):358-364.
32. Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Mitamura K, Tanaka N, Kohda Y. 2004. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 48(10):3813-3816.
33. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053):967-972.
34. Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N. 2013. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology 58(4):1236-1244.
35. Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. 1999. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett 448(1):193-196.
36. Alpini G, Phillips JO, Vroman B, LaRusso NF. 1994. Recent advances in the isolation of liver cells. Hepatology 20(2):494-514.
37. Si-Tayeb K, Lemaigre FP, Duncan SA. 2010. Organogenesis and development of the liver. Dev Cell 18(2):175-189.
38. Mishra N, Yadav NP, Rai VK, Sinha P, Yadav KS, Jain S, Arora S. 2013. Efficient hepatic delivery of drugs: Novel strategies and their significance. Biomed Res Int 2013:382184.